RecruitingPhase 1NCT05683717
A Phase 1 Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies
A Phase I, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell Malignancies
Sponsor
TransThera Sciences (Nanjing), Inc.
Enrollment
37 participants
Start Date
Mar 30, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
This is a multicenter, open-label Phase I dose escalation study to evaluate the safety and preliminary efficacy of the TT-01488 tablet, a non-covalent reversible BTK inhibitor, for the treatment of adult patients with B-cell malignancies.
Eligibility
Min Age: 18 Years
Inclusion Criteria17
- Participants with histologically confirmed B-cell malignancy, failed or intolerant to either ≥ 2 prior standard/common regimens given in combination or sequentially OR have received 1 prior BTK-containing regimen, relapse/refractory, and with treatment indication:
- CLL/SLL treated with prior immunochemistry or BTK inhibitor containing regimen;
- DLBCL treated with prior CD20 or anthracyclines containing regimen;
- Other types of B-cell NHL treated with prior CD20 containing regimen
- Adequate organ function, defined by the following laboratory parameters:
- Hematologic:
- Absolute neutrophil count (ANC) ≥ 0.75×10\^9/L, and ≥ 0.5×10\^9/L if bone marrow involved
- Platelets ≥ 50×10\^9/L without transfusion within 7 days, and ≥ 30×10\^9/L if bone marrow involved
- Hemoglobin ≥ 8.0 g/dL without transfusion within 7 days, and ≥ 7.0 g/dL if bone marrow involved
- Coagulation:
- Prothrombin time (PT) ≤ 1.5 × ULN
- Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN
- Renal function:
- Creatinine clearance ≥ 30 mL/min estimated glomerular filtration rate based on Cockcroft-Gault formula
- Liver function:
- Total bilirubin ≤ 1.5 × ULN (unless due to Gilbert's disease)
- Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≤ 2.5 × ULN unless disease-related
Exclusion Criteria10
- Women who are pregnant or lactating
- Prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer from which the subject has been disease-free for at least 2 years or which will not limit survival to < 2 years (Note: these cases must be discussed with the Medical Monitor and/or Investigator)
- Significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months of screening, or significant screening ECG abnormalities
- Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel or ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction
- History of allogeneic or autologous stem cell transplant (SCT) or chimeric antigen receptor-modified T-cell (CAR-T) therapy within the past 60 days or with any of the following:
- Active graft versus host disease (GvHD);
- Cytopenias from incomplete blood cell count recovery post-transplant;
- Need for anti-cytokine therapy for toxicity from CAR-T therapy; residual symptoms of neurotoxicity > Grade 1 from CAR-T therapy;
- Ongoing immunosuppressive therapy
- Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy, including radiation
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DRUGTT-01488 Tablets
TT-01488 tablet will be administered orally once daily per protocol defined schedule.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05683717
Related Trials
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT0727166711 locations
A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.
NCT0654225030 locations
Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies
NCT073498491 location
A Phase 1/2 Study of T-cell Expressing an Anti-CD22 Chimeric-Antigen Receptor (SHB-04-CD22) in Patients With CD22-expressing B-cell Malignancies
NCT071354661 location
A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies
NCT030501902 locations